Skp2 在卵巢上皮性肿瘤中的表达及临床意义

 目的 检测S期激酶相关蛋白2(S-phase kinase associated protein2, Skp2)在卵巢上皮性肿瘤中的表达,探讨其表达与上皮性卵巢癌临床病理参数之间的关系,以及了解其表达在卵巢上皮性肿瘤发生、发展及上皮性卵巢癌预后估计中的意义. 方法 收集我院81例卵巢上皮性肿瘤的外科手术石蜡标本,用免疫组化的方法检测Skp2的表达水平. 结果 Skp2在卵巢上皮性良性肿瘤及交界性肿瘤中表达均为阴性,而在上皮性卵巢癌中表达率为46.43%(26/56),半定量分析表明Skp2在不同年龄及组织类型的卵巢癌中表达无显著性差异(P>0.05),而在中低度分化组、Ⅲ～Ⅳ期组及有淋巴结转移组分别明显高于高分化组(P<0.01)、Ⅰ～Ⅱ期组(P<0.01)及无淋巴结转移组(P<0.01). 结论 Skp2特异性表达于上皮性卵巢癌,其表达水平越高提示病人预后越差.

Expression of Skp2 in Epithelial Ovarian Tumors and Its Clinical Significance

Objective This study detected the expression of Skp2 in epithelial ovarian tumors and analyzed the relationship between its expression levels and clinicopathological parameters in ovarian adenocarcinomas. The purpose is to explore its role in the tumorigenesis and development of epithelial ovarian tumors and to identify its significance in evaluating the prognosis of ovarian adenocarcinomas.Methods Expression of Skp2 was examined by immunohistochemistry in 81 epithelial ovarian tumors 13 adenomas,12 borderline adenomas,and 56 adenocarcinomas]. Results of immunohistochemistry were correlated with clinicopathological variables.Results Expression of Skp2 was detected in neither ovarian adenomas nor borderline adenomas.In contrast, it was detected in 46.43% (26/56) of adenocarcinomas. Positive expression of Skp2 was detected significantly more often in adenocarcinomas than that of borderline adenomas (P< 0.0001),which was significantly more often than that of adenomas (P< 0.0001) in turn. Counting the percentage of positive cells of 26 adenocarcinomas with Skp2 positive expression indicated that the expression level of Skp2 was significantly higher in advanced-grade specimens compared with early-grade ones(P<0.01).In addition,the level of Skp2 expression also significantly associated with clinical stage(P<0.01)and positive lymph node metastasis (P< 0.05)of ovarian adenocarcinomas.Conclusion Skp2 expression may play an important role in the development and progression of ovarian adenocarcinomas, and Skp2 expression can be used as a assistant marker of estimating the prognosis of ovarian adenocarcinomas patients.The higher expression levels indicates poorer prognosis.